A preliminary economic evaluation of percutaneous neuromuscular electrical stimulation in the treatment of hemiplegic shoulder pain

Disabil Rehabil. 2006 May 30;28(10):645-51. doi: 10.1080/09638280500277057.

Abstract

Objective: The objective of this study was to compare the cost-effectiveness of various treatment modalities for hemiplegic shoulder pain.

Design: A stage II economic evaluation.

Main outcome measures: Incremental cost effectiveness ratio of P-NMES, compared to slings and anti-inflammatory injections.

Results: The incremental cost effectiveness ratio (ICER) of p-NMES, compared to anti-inflammatory injections is 6,061 euro(+/-3,285). The incremental cost of the first quality-adjusted life year after implantation of the P-NMES device compared to anti-inflammatory injections is 33,007 euro (+/-5,434). This decreases to approximately 7,000 euro after 5 years, and to approximately 5,000 euro after 10 survival years.

Conclusion: In this early evaluation, P-NMES seems to be cost-effective according to known guidelines. Treatment with P-NMES is recommended for patients with chronic HSP.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / economics
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Chronic Disease
  • Cost-Benefit Analysis
  • Direct Service Costs*
  • Electric Stimulation Therapy / economics*
  • Electric Stimulation Therapy / methods
  • Electrodes, Implanted
  • Hemiplegia / complications
  • Hemiplegia / economics
  • Hemiplegia / rehabilitation*
  • Humans
  • Models, Econometric
  • Netherlands
  • Quality-Adjusted Life Years
  • Restraint, Physical
  • Shoulder Pain / economics
  • Shoulder Pain / etiology
  • Shoulder Pain / therapy*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal